<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
For Quarter Ended September 30, 1997 Commission File Number 0-19373
BIOMATRIX, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 13-3058261
- ------------------------------- ---------------------------------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
65 Railroad Avenue, Ridgefield, N.J. 07657
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(201)945-9550
----------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
(1) Yes [ X ] No [ ]
The number of shares outstanding of the issuer's common stock as of the latest
practicable date:
<TABLE>
<CAPTION>
Class September 30, 1997
----- ------------------
<S> <C>
Common stock, $ 0.0001 par value 10,947,753
</TABLE>
<PAGE> 2
BIOMATRIX, INC.
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE NO.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1 - Unaudited Consolidated Financial Statements
Consolidated Balance Sheets as of
September 30, 1997 and December 31, 1996 3
Consolidated Statements of Operations for the Three
and Nine Months Ended September 30, 1997 and 1996 4
Consolidated Statements of Cash Flows for the
Nine Months Ended September 30, 1997 and 1996 5
Notes to Consolidated Financial Statements 6-7
ITEM 2
Management's Discussion and Analysis of Financial
Condition and Results of Operations 8-11
PART II. OTHER INFORMATION
ITEM 2
Changes in Securities 12
ITEM 6
Exhibits and Reports on Form 8-K 12
Signatures 13
</TABLE>
2
<PAGE> 3
BIOMATRIX, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
September 30, December 31,
1997 1996
------------ ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 21,296,372 $ 3,034,764
Held-to-maturity investments 1,400,375 10,603,358
Accounts receivable, less allowance for doubtful accounts
of $25,500 in 1997 and 1996 1,304,278 1,230,456
Inventory, at lower of cost or market 2,827,096 727,083
Prepaid expenses and other current assets 1,620,737 730,302
------------ ------------
Total current assets 28,448,858 16,325,963
Property, plant and equipment, net 13,804,633 9,506,005
Other assets 277,019 162,059
------------ ------------
Total assets $ 42,530,510 $ 25,994,027
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of notes payable and capital lease obligations $ 153,279 $ 167,408
Accounts payable 682,829 724,743
Accrued expenses 2,886,947 1,599,419
------------ ------------
Total current liabilities 3,723,055 2,491,570
Notes payable and capital lease obligations
less current maturities 5,696,943 5,798,522
------------ ------------
Total liabilities 9,419,998 8,290,092
------------ ------------
Commitments and contingent liabilities
Shareholders' equity:
Common stock, $.0001 par value: 60,000,000 shares authorized;
10,993,900 and 10,587,615 issued and 10,947,753 and
10,584,801 outstanding in 1997 and 1996, respectively 1,100 1,059
Preferred stock, 3,000 shares authorized; none issued - -
Notes receivable - related parties (2,868,538) (2,450,000)
Additional paid-in capital 59,840,676 56,682,755
Accumulated deficit (21,975,259) (35,564,348)
Equity adjustment from foreign currency translation (946,556) (953,571)
Treasury stock, 46,147 and 2,814 shares of common stock at cost
at September 30, 1997 and December 31, 1996, respectively (940,911) (11,960)
------------ ------------
Total shareholders' equity 33,110,512 17,703,935
------------ ------------
Total liabilities and shareholders' equity $ 42,530,510 $ 25,994,027
============ ============
</TABLE>
The accompanying notes are an integral
part of the consolidated financial statements
3
<PAGE> 4
BIOMATRIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------------- -------------------------------
1997 1996 1997 1996
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
Revenues:
Net sales $ 1,754,041 $ 1,120,114 $ 5,504,366 $ 3,281,592
Income from licenses, royalties,
and research contracts 12,113,256 1,345,225 19,390,588 9,465,334
------------ ------------ ------------ ------------
Total revenues 13,867,297 2,465,339 24,894,954 12,746,926
------------ ------------ ------------ ------------
Cost and expenses:
Cost of sales 558,126 535,212 1,987,949 1,890,573
Research and development expenses 1,531,796 1,623,653 4,337,901 4,526,306
Selling, general and
administrative expenses 1,968,748 1,045,849 5,269,967 3,409,183
------------ ------------ ------------ ------------
Total costs and expenses 4,058,670 3,204,714 11,595,817 9,826,062
------------ ------------ ------------ ------------
Income (loss) from operations 9,808,627 (739,375) 13,299,137 2,920,864
Interest expense (17,893) (24,719) (73,254) (91,094)
Interest and miscellaneous income 257,604 189,608 684,206 551,057
------------ ------------ ------------ ------------
Income (loss) before taxes 10,048,338 (574,486) 13,910,089 3,380,827
------------ ------------ ------------ ------------
Provision for income taxes 260,000 - 321,000 -
------------ ------------ ------------ ------------
Net income (loss) $ 9,788,338 $ (574,486) $ 13,589,089 $ 3,380,827
============ ============ ============ ============
Net income (loss) per common and
common equivalent share $ 0.85 $ (0.05) $ 1.21 $ 0.33
============ ============ ============ ============
Weighted average common and common
equivalent shares outstanding 11,461,406 10,467,930 11,212,686 10,336,078
============ ============ ============ ============
</TABLE>
The accompanying notes are an integral
part of the consolidated financial statements
4
<PAGE> 5
BIOMATRIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Nine Months Ended
September 30,
-------------------------------
1997 1996
------------ ------------
<S> <C> <C>
Cash flows from operating activities:
Net income $ 13,589,089 $ 3,380,827
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 480,024 404,128
Stock option compensation 56,388 27,364
Change in assets and liabilities:
Accounts receivable (76,155) 179,903
Inventory (2,111,378) 54,744
Prepaid expenses and other current assets (921,135) (288,527)
Other assets (150,155) (359)
Accounts payable and accrued expenses 1,465,037 324,645
------------ ------------
Net cash provided by operating activities 12,331,715 4,082,725
------------ ------------
Cash flows from investing activities:
Maturity of held-to-maturity securities 9,202,983 6,820,349
Purchases of held-to-maturity securities - (16,446,721)
Capital expenditures (4,795,278) (502,177)
------------ ------------
Net cash provided by (used for) investing activities 4,407,705 (10,128,549)
------------ ------------
Cash flows from financing activities:
Payments of notes payable and capital lease obligations (115,483) (184,788)
Sale of common stock to related parties 1,890,000 -
Purchase of treasury stock (928,951) -
Stock options exercised 705,850 721,565
------------ ------------
Net cash provided by financing activities 1,551,416 536,777
------------ ------------
Effect of exchange rate changes on cash (29,228) (5,374)
------------ ------------
Net increase (decrease) in cash and cash equivalents 18,261,608 (5,514,421)
Cash and cash equivalents at beginning of period 3,034,764 8,888,869
------------ ------------
Cash and cash equivalents at end of period $ 21,296,372 $ 3,374,448
============ ============
Supplemental cash flow data:
Interest paid, net of capitalized interest $ 73,254 $ 91,094
Taxes paid $ 140,000 -
Non-cash financing activities:
Sale of common stock financed with notes receivable $ 398,250 $ 2,450,000
</TABLE>
The accompanying notes are an integral
part of the consolidated financial statements
5
<PAGE> 6
BIOMATRIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - BASIS OF PRESENTATION
The consolidated financial statements at September 30, 1997 and for the
three and nine months ended September 30, 1997 and 1996 are unaudited, but
include all adjustments which the Company considers necessary for a fair
presentation of the financial position at such date and the operating results
and cash flows for those periods. These condensed consolidated financial
statements should be read in conjunction with the Company's audited consolidated
financial statements for the year ended December 31, 1996, which were included
as part of the Company's Form 10-K, filed with the Securities and Exchange
Commission. Results for the interim periods are not necessarily indicative of
results for the entire year.
NOTE 2 - CONTINGENCIES
In August 1990, the Company received a notice from the Pennsylvania
Department of Environmental Resources ("DER") that it is one of approximately
1,000 potentially responsible parties ("PRPs") that may have clean-up
responsibility at the Industrial Solvents and Chemical Company site in York
Haven, Pennsylvania (the "Site"). During the late 1980s, the Company, through a
licensed waste disposal transport company, shipped industrial solvents to the
Site, which was operating as a recycling facility. The DER reviewed hazardous
waste found at the Site as well as the DER's own records in order to identify
additional PRPs and to quantify each PRPs volumetric contributions. The Company
is a member of a steering committee that consists of many PRPs. Although neither
the total clean-up cost nor the portion of the total clean-up cost assigned to
each PRP has been determined, the Company estimated, based upon the advice of a
consultant, that its liability would be approximately $780,000. Further, the
same consultant has reported to the Company that there is less than a 10% chance
that its liability might exceed $1,070,033. During the second quarter of 1995
the Company paid its first assessment for clean-up costs of $79,390.
Additionally, the Company paid $15,000 during the first quarter of 1997;
therefore, the reserve at September 30, 1997 represented $685,610. The steering
committee for the PRPs has prepared a buy-out proposal pursuant to a consent
order with the DER. This buy-out proposal identifies each PRP's assigned portion
of assumed total clean-up costs. When the final remedy is selected by the DER,
the Company plans to settle out of the matter pursuant to the buyout proposal.
The Company will monitor this situation and make any necessary adjustments to
the reserve once additional information is available with regard to the DER's
acceptance of the steering committee's proposal.
In October 1996, Michael Jarcho ("Jarcho") filed suit in the United
States District Court for the Southern District of California seeking to recover
damages and declaratory judgment for the alleged breach by the Company of
Jarcho's consulting agreement. A consulting agreement had been entered into
between the Company and Jarcho on December 2, 1988. The agreement contains
certain royalty provisions for products that result from Jarcho's consultancy.
Jarcho contends, inaccurately in the Company's view, that Hylaform resulted from
his consultancy. Jarcho seeks compensatory damages of $300,000 plus a royalty on
the Company's net sales of Hylaform as well as punitive damages and recovery of
attorney fees. The Company believes that no royalties are owed Jarcho as a
result of Hylaform sales. Jarcho's case was dismissed on January 10, 1997, on
the grounds that the agreement requires such disputes to be brought exclusively
in New Jersey state court. Jarcho moved for a partial reconsideration of the
decision, the Company opposed that request, and the request was denied. On June
16, 1997 Jarcho filed suit in New Jersey state court. The Company intends to
defend this matter vigorously. However, the ultimate outcome of this litigation
is unknown at the present time, and accordingly, it could have a material
adverse impact on the Company's financial position, results of operations and
cash flows. The Company has not made any provision on the accompanying
consolidated financial statements for any liability that might result.
6
<PAGE> 7
BIOMATRIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
NOTE 3 - INVENTORIES
Inventories at September 30, 1997 and December 31, 1996 consisted of:
<TABLE>
<CAPTION>
September 30, December 31,
1997 1996
---------- --------
<S> <C> <C>
Finished Goods $ 343,473 $148,925
Work-in-Process 1,112,861 300,704
Raw Materials 1,370,762 277,454
---------- --------
$2,827,096 $727,083
========== ========
</TABLE>
NOTE 4 - NOTES RECEIVABLE - RELATED PARTIES
The notes receivable - related parties relates to the acquisition of
common stock of the Company by several officers of the Company during 1996 and
1997. The notes are with recourse and payable with interest upon maturity. All
notes issued during 1997 have been for common stock issued pursuant to the
Company's 1997 Restricted Stock Plan.
NOTE 5 - IMPACT OF THE ADOPTION OF RECENTLY ISSUED ACCOUNTING STANDARDS
In February 1997, the Financial Accounting Standards Board ("FASB")
issued Statement of Financial Accounting Standards No. 128 "Earnings per Share"
which changes the reporting requirements for earnings per share ("EPS") for
publicly traded companies by replacing primary EPS with basic EPS and requiring
the dual presentation of basic and diluted EPS on the face of the consolidated
statements of operations. The Company is required to adopt this standard in its
December 31, 1997 financial statements. Had the new standard been in effect on
September 30, 1997 the Company would have experienced no material impact from
adoption.
In June 1997, the FASB issued Statement of Financial Accounting
Standards No. 130 "Reporting Comprehensive Income" which establishes standards
for reporting and display of comprehensive income and its components in a full
set of financial statements. The Company is required to adopt this standard in
1998 and believes the principle component of comprehensive income will be
foreign currency translation.
In June 1997, the FASB issued Statement of Financial Accounting
Standards No. 131 "Disclosures about Segments of an Enterprise and Related
Information" which establishes standards for the way that public enterprises
report information about operating segments, geographic areas, products and
major customers. The Company is required to adopt this standard in 1998 and is
currently evaluating the impact of this standard.
7
<PAGE> 8
BIOMATRIX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Biomatrix, Inc., together with its subsidiaries (the "Company"), is
principally engaged in the research, development and commercial application of
proprietary viscoelastic biological polymers, called hylans, for use in
therapeutic medical applications and skin care. For approximately the past three
years, a significant source of revenue for the Company has been from certain
up-front payments relating to corporate license and distribution agreements. The
Company expects milestone payments from existing agreements and other one-time
payments from partners to continue to be an important source of revenues.
The Company's business is subject to significant risks. Forward-looking
comments included herein are subject to and should be read in conjunction with
the "Risk Factors" section of the Company's 1996 Annual Report on Form 10-K,
including the risks and uncertainties associated with the regulatory approval
process, with obtaining and enforcing patents important to the Company's
business, competition, dependence upon marketing partners, and other risks
detailed in the Company's reports filed under the Securities Exchange Act. As a
significant amount of Biomatrix' future revenues may be based on payments from
corporate distribution agreements, the Company's total revenues and income or
losses are expected to fluctuate from quarter-to-quarter. Some of these
fluctuations may be significant and, as a result, quarter-to-quarter comparisons
may not be meaningful. As of September 30, 1997, the Company's accumulated
deficit was $21,975,259.
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1997 AND 1996
REVENUES. Total revenues for the three months ended September 30,
1997 were $13,867,297, an increase of $11,401,958 from the same period in 1996.
Product sales for the three months ended September 30, 1997 were $1,754,041,
representing an increase of $633,927 or 57%, over the same period in 1996. This
increase was primarily attributable to new sales of Synvisc to the Company's
partners in Germany and France, new sales of Hylaform to the Company's partner
in Europe, and an increase in skin care product sales. Revenues from licenses,
royalties, and research contracts were $12,113,256 in the third quarter of 1997,
which was primarily attributable to a non-refundable license fee payment of $12
million from Wyeth-Ayerst Laboratories which was received as a result of the
Company's receipt of Food and Drug Administration (FDA) approval to market
Synvisc in the United States.
COST AND EXPENSES. Total cost and expenses for the third quarter of
1997 were $4,058,670, an increase of $853,956, or 27%, from the same period in
1996. Cost of sales for the third quarter of 1997 and 1996 were $558,126 and
$535,212, respectively, which represented 32% and 48% of sales, respectively.
The decrease in the percentage of cost of sales to sales was primarily a result
of increased production volumes and better utilization of capacities. Research
and development expenses in the third quarter were $1,531,796, representing a
decrease of $91,857, or 6%, from the same period of 1996. Selling, general and
administrative expenses for the third quarter of 1997 were $1,968,748,
representing an increase of $922,899, or 88%, over the third quarter of 1996.
The increase in selling, general and administrative was primarily attributable
to costs associated with a greater number of personnel and expenses associated
with preparing for the launch of Synvisc in the United Sates, the establishment
of European operations, and the expansion of operations in Canada and the United
States.
INTEREST AND MISCELLANEOUS INCOME. Interest expense was $17,893 for the
third quarter of 1997, a decrease of $6,286 from the same period of 1996.
Interest and miscellaneous income was $257,604 for the third quarter of 1997, an
increase of $67,996 from the same period in 1996. The increase in interest and
miscellaneous income was due primarily to greater interest income resulting from
higher average cash and investment balances.
8
<PAGE> 9
BIOMATRIX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1997, AND 1996
REVENUES. Total revenues for the nine months ended September 30, 1997
and 1996 were $24,894,954 and $12,746,926, respectively, which represented an
increase of $12,148,028 in the 1997 period. Product sales were $5,504,366 in the
first nine months of 1997, representing an increase of $2,222,774 or 68%, over
the same period in 1996. This increase was due primarily to new sales of Synvisc
to the Company's partners in Germany and France, new sales of Hylaform to the
Company's partner in Europe, and increased sales of skin care products. Product
sales accounted for 22% and 26% of total revenues for the nine months ended
September 30, 1997 and 1996, respectively. Revenues from research contracts,
licenses and royalties were $19,390,588 and $9,465,334 for the nine months ended
September 30, 1997 and 1996, respectively, and accounted for 78% and 74% of
total revenues in the nine months ended September 30, 1997 and 1996,
respectively.
COST AND EXPENSES. Total cost and expenses were $11,595,817 for the
nine months ended September 30, 1997, which represented an increase of
$1,769,755, or 18%, from the corresponding period of 1996. Cost of sales was
$1,987,949 for the nine months ended September 30, 1997, representing an
increase of $97,376 over the same period in 1996. Cost of sales as a percentage
of sales was 36% in the nine months ended September 30, 1997 versus 58% for the
same period of 1996. The reduction in the cost of sales as a percentage of sales
is due to savings resulting from capacity utilization and production
efficiencies. Research and development expenses were $4,337,901 in the first
three quarters of 1997, representing a decrease of $188,405 or 4%. Selling,
general and administrative expenses were $5,269,967 in the first nine months of
1997, representing an increase of $1,860,784, or 55%, over the same period in
1996. The increase was due primarily to costs associated with the negotiation of
corporate distribution and joint venture agreements, higher personnel and
consulting expenses associated with preparing for the launch of Synvisc in the
United States, the establishment of European operations, and the expansion of
operations in Canada and the United States.
INTEREST AND MISCELLANEOUS INCOME. Interest expense was $73,254 for the
first nine months of 1997, which represented a decrease of $17,840 from the same
period of 1996. Interest and miscellaneous income was $684,206 for the nine
months ended September 30, 1997 as compared to $551,057 for the same period of
1996. The increase in interest and miscellaneous income was due primarily to
greater interest income resulting from higher average cash and investment
balances.
LIQUIDITY AND CAPITAL RESOURCES
The Company had cash and cash equivalents of $21,296,372 and
held-to-maturity investments, invested in U.S. government securities, of
$1,400,375 at September 30, 1997. Overall, the Company's cash and
held-to-maturity investment position increased by $9,058,625 in the nine months
ended September 30, 1997. The Company invests its excess cash in U.S. government
securities. Any security purchased with a maturity of three months or less is
classified as cash and cash equivalents.
The Company's operations over the past several years have been financed
primarily from the private placement of equity securities and up-front
non-refundable license fee payments from corporate partners. Over the past three
years, the Company has received funding of $7,717,775 from the private placement
of equity securities and $38,533,000 from license fee payments.
9
<PAGE> 10
BIOMATRIX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
LIQUIDITY AND CAPITAL RESOURCES (CONTINUED)
For the nine months ended September 30, 1997 the Company had positive
cash flows from operations of $12,331,715 which primarily resulted from
non-recurring fees received during the nine months of $19,000,000, offset by
expenditures made to increase inventory levels and fund operations. During the
nine month period, the Company invested $4,795,278 in property, plant, and
equipment, primarily associated with increasing the production capacity of its
Canadian manufacturing facility and the capitalization of costs related to a
lease which the Company entered into for a 93,000 square foot building in New
Jersey in which the Company intends to locate its U.S. manufacturing operation.
The lease term is approximately ten years with annual lease payments increasing
from $350,000 to $500,000 over the term of the lease. Within the first three
years of the lease, the Company has an option to acquire this building at a
price of approximately $4,500,000. Should the Company not exercise its option
within this three-year period, the landlord has the right to require the Company
to purchase this building for approximately the same price. The Company plans to
continue to modify this building to accommodate manufacturing capability for the
U.S. and foreign markets. The Company also plans to relocate its executive and
administrative offices and research and development laboratories to this
building upon the expiration in 1999 of the Company's lease on its current
headquarters in New Jersey. Additionally, the Company received $705,850 from the
exercise of Company stock options and $1,890,000 from the sale of common stock
during the nine months ended September 30, 1997.
In February 1997, the Company entered into a marketing and
distribution agreement with Wyeth-Ayerst Laboratories ("Wyeth") to sell Synvisc
in the United States, Germany, Austria, Spain, Portugal, Greece and certain
countries in the Middle East and Central Europe. As part of this agreement,
the Company received a non-refundable upfront license fee payment of
$4,000,000. During the third quarter, the Company also received $12,000,000
related to the Food and Drug Administration's approval of Synvisc in the United
States. In addition, during the fourth quarter the Company has received
$1,000,000 related to the launch of Synvisc in Germany. The Company is
scheduled to receive an additional $6,000,000 milestone payment during the
fourth quarter of 1998 related to the first anniversary of the launch of
Synvisc in the United States. The Company could receive additional milestone
payments related to achieving certain sales levels.
In April 1997, the Company entered into a marketing and distribution
agreement with Bayer AG ("Bayer") to sell Synvisc in Australia, New Zealand,
Taiwan, Singapore, Indonesia, Thailand, Malaysia and Israel. In return, the
Company received an up front non-refundable license fee payment of $3,000,000,
and could receive an additional milestone payment of $2,000,000.
The planned increase in manufacturing capacity and commercialization of
medical products will continue to increase costs and expenses during the
remainder of 1997. The Company's capital spending associated with developing its
additional capacity is expected to approximate $5,000,000 during the remainder
of 1997. The Company plans to seek lease financing which, if obtained, could
fund a portion of these capital costs. The Company will continue to incur higher
expenses during 1997 associated with developing its internal infrastructure to
support the administration of its sales force for its distribution agreements
with Boehringer Ingelheim France, S.A., Wyeth, and Bayer, as well as the
establishment of a sales and marketing function for the Company's direct sales
in certain European and Asian countries. The Company believes that its capital
needs and higher operating expenses will be supported by its current working
capital position, potential milestone payments from existing corporate partners,
and other one-time payments from partners.
10
<PAGE> 11
BIOMATRIX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
During the second quarter of 1997, the Company committed to repurchase
86,666 shares of common stock from one of its partners, Recordati International
Holdings, S.A. ("Recordati"), as was the Company's right under a Stock Purchase
Agreement entered into with Recordati in 1995. Also during the second quarter,
the Company sold 105,000 shares of common stock at fair market value to certain
officers of the Company under the 1997 Restricted Stock Purchase Plan. The sale
of these shares to the officers at fair market value were settled in cash by the
close of the second quarter and generated $1,890,000 of proceeds to the Company.
The Company repurchased 43,333 of the shares from Recordati during the third
quarter, which required approximately $929,000 of funds. The repurchased shares
are included as treasury stock on the balance sheet. The Company still has the
right to repurchase 33,333 shares during the next three months upon notice of
sale from Recordati.
In February 1997, the Financial Accounting Standards Board ("FASB")
issued Statement of Financial Accounting Standards No. 128 "Earnings per Share"
which changes the reporting requirements for earnings per share ("EPS") for
publicly traded companies by replacing primary EPS with basic EPS and requiring
the dual presentation of basic and diluted EPS on the face of the consolidated
statements of operations. The Company is required to adopt this standard in its
December 31, 1997 financial statements. Had the new standard been in effect on
September 30, 1997 the Company would have experienced no material impact from
adoption.
In June 1997, the FASB issued Statement of Financial Accounting
Standards No. 130 "Reporting Comprehensive Income" which establishes standards
for reporting and display of comprehensive income and its components in a full
set of financial statements. The Company is required to adopt this standard in
1998 and believes the principle component of comprehensive income will be
foreign currency translation.
In June 1997, the FASB issued Statement of Financial Accounting
Standards No. 131 "Disclosures about Segments of an Enterprise and Related
Information" which establishes standards for the way that public enterprises
report information about operating segments, geographic areas, products and
major customers. The Company is required to adopt this standard in 1998 and is
currently evaluating the impact of this standard.
11
<PAGE> 12
BIOMATRIX, INC. AND SUBSIDIARIES
ITEM 2. CHANGES IN SECURITIES
On May 29, 1997, the shareholders approved the Company's 1997
Restricted Stock Purchase Plan (the "Plan"). Pursuant to the Plan, the Company
sold 6,000 shares of common stock to each of Dr. Janet L. Denlinger, Mr. Rory B.
Riggs, and Mr. Justin P. Morreale, at a purchase price of $15.875 per share
(such price being the closing price on May 28, 1997). Dr. Denlinger, Mr. Riggs,
and Mr. Morreale each purchased the shares described above with a full recourse,
ten-year, secured promissory note that accrues interest at the rate of 7.18% per
year. Such shares are pledged to the Company as collateral for the notes. Such
shares are subject to repurchase by the Company according to agreements between
the Company and each of Dr. Denlinger and Mr. Riggs, as applicable.
On the same date, the Board of Directors approved Dr. Denlinger and Mr.
Riggs each foregoing a previous option grant of 5,000 shares at a price of
$11.25 per share in exchange for the purchase of 5,000 shares under the Plan.
Dr. Denlinger and Mr. Riggs each purchased the shares with an interest bearing,
full recourse, ten-year, secured promissory note equal to the underlying option
price per share. Both officers recognized a gain on this conversion based on the
fair market value of $15.875 per share as of May 28, 1997. Such shares are
pledged to the Company as collateral for the notes and are subject to repurchase
by the Company according to agreements between the Company and each of Dr.
Denlinger and Mr. Riggs, as applicable.
These shares were issued pursuant to the shareholder approved Plan,
however, because the Plan was not yet filed with the Securities and Exchange
Commission the shares were sold in private offerings, which the Company believes
qualify as transactions by an issuer not involving a public offering within the
meaning of Section 4(2) of the Securities Act of 1933, as amended.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
A. EXHIBITS
11 Computation of Earnings Per Share
27.1 Financial Data Schedule
B. REPORTS ON FORM 8-K
None
12
<PAGE> 13
BIOMATRIX, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE: October 31, 1997 BIOMATRIX, INC.
By: /s/Endre A. Balazs
-------------------------------
Endre A. Balazs
Chief Executive Officer and
Chief Scientific Officer
By: /s/Rory B. Riggs
-------------------------------
Rory B. Riggs
President and Chief Financial Officer
13
<PAGE> 1
BIOMATRIX, INC. AND SUBSIDIARIES
EXHIBIT 11
COMPUTATION OF EARNINGS PER SHARE
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30, 1997 September 30, 1997
----------- -----------
<S> <C> <C>
Income applicable to common shares $ 9,788,338 $13,589,089
Weighted-average number of common shares and common
share equivalents outstanding during the period:
Common Stock 10,949,389 10,820,664
Stock options - primary 512,017 392,022
----------- -----------
Shares outstanding - primary 11,461,406 11,212,686
Stock options - fully diluted 54,938 174,933
----------- -----------
Shares outstanding - fully diluted 11,516,344 11,387,619
Primary earnings per common share $ 0.85 $ 1.21
Fully diluted earnings per common share $ 0.85 $ 1.19
</TABLE>
14
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> SEP-30-1997
<CASH> 21,296,372
<SECURITIES> 1,400,375
<RECEIVABLES> 1,329,778
<ALLOWANCES> 25,500
<INVENTORY> 2,827,096
<CURRENT-ASSETS> 28,448,858
<PP&E> 17,850,898
<DEPRECIATION> (4,046,265)
<TOTAL-ASSETS> 42,530,510
<CURRENT-LIABILITIES> 3,723,055
<BONDS> 5,850,222
0
0
<COMMON> 59,841,776
<OTHER-SE> (4,756,005)
<TOTAL-LIABILITY-AND-EQUITY> 42,530,510
<SALES> 5,504,366
<TOTAL-REVENUES> 24,894,954
<CGS> 1,987,949
<TOTAL-COSTS> 11,595,817
<OTHER-EXPENSES> 73,254
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 73,254
<INCOME-PRETAX> 13,910,089
<INCOME-TAX> 321,000
<INCOME-CONTINUING> 13,589,089
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 13,589,089
<EPS-PRIMARY> 1.21
<EPS-DILUTED> 1.19
</TABLE>
